| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H16F3NO |
| Molecular Weight | 295.2995 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCC[C@H](OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2
InChI
InChIKey=WIQRCHMSJFFONW-HNNXBMFYSA-N
InChI=1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2/t15-/m0/s1
| Molecular Formula | C16H16F3NO |
| Molecular Weight | 295.2995 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Seproxetine, also known as (S)-norfluoxetine, is a selective serotonin reuptake inhibitor (SSRI). It is the most important active metabolite of the widely used antidepressant fluoxetine, but little is known about its pharmacological actions. Seproxetine was being investigated by Eli Lilly and Company as an antidepressant; however, a cardiac side effect was noted and development was discontinued.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 4544.0 nM [Ki] | |||
| 6186.0 nM [Ki] | |||
| 50.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Patents
Sample Use Guides
Rat cortical membranes equivalent to 50 mkg of protein were incubated at 37°C for 30 minutes in 2 ml of reaction medium containing the (S)-Norfluoxetine (1-1000nM), 0.1 nM [3Hlparoxetine, 50 mmol/L Tris-HG, pH 7.4, 150 mmol/L NaG, and 5 mmol/L KCl. Fluoxetine at 1 mkM/kg was used to determine nonspecific binding
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 1 of 1 entries
